319 related articles for article (PubMed ID: 14648018)
41. Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding.
Curtin NJ; Bowman KJ; Turner RN; Huang B; Loughlin PJ; Calvert AH; Golding BT; Griffin RJ; Newell DR
Br J Cancer; 1999 Aug; 80(11):1738-46. PubMed ID: 10468290
[TBL] [Abstract][Full Text] [Related]
42. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines.
Tanaka R; Takii Y; Shibata Y; Ariyama H; Qin B; Baba E; Kusaba H; Mitsugi K; Harada M; Nakano S
Cancer Chemother Pharmacol; 2005 Sep; 56(3):279-85. PubMed ID: 15875187
[TBL] [Abstract][Full Text] [Related]
43. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
[TBL] [Abstract][Full Text] [Related]
44. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
[TBL] [Abstract][Full Text] [Related]
45. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Takagi K; Sowa Y; Cevik OM; Nakanishi R; Sakai T
Int J Oncol; 2008 May; 32(5):1105-10. PubMed ID: 18425338
[TBL] [Abstract][Full Text] [Related]
46. Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition.
Koehler SE; Ladner RD
Mol Pharmacol; 2004 Sep; 66(3):620-6. PubMed ID: 15322254
[TBL] [Abstract][Full Text] [Related]
47. Radiosensitization by fluorodeoxyuridine: effects of thymidylate synthase inhibition and cell synchronization.
Miller EM; Kinsella TJ
Cancer Res; 1992 Apr; 52(7):1687-94. PubMed ID: 1532343
[TBL] [Abstract][Full Text] [Related]
48. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.
Yeh KH; Yeh SH; Hsu CH; Wang TM; Ma IF; Cheng AL
Br J Cancer; 2000 Dec; 83(11):1510-5. PubMed ID: 11076661
[TBL] [Abstract][Full Text] [Related]
49. Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
Mueller S; Schittenhelm M; Honecker F; Malenke E; Lauber K; Wesselborg S; Hartmann JT; Bokemeyer C; Mayer F
Int J Oncol; 2006 Aug; 29(2):471-9. PubMed ID: 16820891
[TBL] [Abstract][Full Text] [Related]
50. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
Webley SD; Hardcastle A; Ladner RD; Jackman AL; Aherne GW
Br J Cancer; 2000 Sep; 83(6):792-9. PubMed ID: 10952785
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
52. Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.
van der Wilt CL; Backus HH; Smid K; Comijn L; Veerman G; Wouters D; Voorn DA; Priest DG; Bunni MA; Mitchell F; Jackman AL; Jansen G; Peters GJ
Cancer Res; 2001 May; 61(9):3675-81. PubMed ID: 11325838
[TBL] [Abstract][Full Text] [Related]
53. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells.
Marverti G; Ligabue A; Paglietti G; Corona P; Piras S; Vitale G; Guerrieri D; Luciani R; Costi MP; Frassineti C; Moruzzi MS
Eur J Pharmacol; 2009 Aug; 615(1-3):17-26. PubMed ID: 19446547
[TBL] [Abstract][Full Text] [Related]
54. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery.
De Angelis PM; Svendsrud DH; Kravik KL; Stokke T
Mol Cancer; 2006 May; 5():20. PubMed ID: 16709241
[TBL] [Abstract][Full Text] [Related]
55. Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by Mycoplasma infection.
Jetté L; Bissoon-Haqqani S; Le François B; Maroun JA; Birnboim HC
Anticancer Res; 2008; 28(4B):2175-80. PubMed ID: 18751392
[TBL] [Abstract][Full Text] [Related]
56. Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death.
Shinomiya N; Shinomiya M; Wakiyama H; Katsura Y; Rokutanda M
Exp Cell Res; 1994 Feb; 210(2):236-42. PubMed ID: 8299722
[TBL] [Abstract][Full Text] [Related]
57. Drug resistance in colon cancer.
Gorlick R; Bertino JR
Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253
[TBL] [Abstract][Full Text] [Related]
58. Gonadotropin-releasing hormone retards doxorubicin-induced apoptosis and serine/threonine phosphatase inhibition in ovarian cancer cells.
Sugiyama M; Imai A; Furui T; Tamaya T
Oncol Rep; 2005 May; 13(5):813-7. PubMed ID: 15809743
[TBL] [Abstract][Full Text] [Related]
59. Radiosensitization of tumour cells by cantharidin and some analogues.
Price WA; Stobbe CC; Park SJ; Chapman JD
Int J Radiat Biol; 2004 Apr; 80(4):269-79. PubMed ID: 15204704
[TBL] [Abstract][Full Text] [Related]
60. Enhanced cytotoxicity with interleukin-1 alpha and 5-fluorouracil in HCT116 colon cancer cells.
Geoffroy FJ; Allegra CJ; Sinha B; Grem JL
Oncol Res; 1994; 6(12):581-91. PubMed ID: 7787251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
